These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 24405719)

  • 21. Adherence in the CAPRISA 004 tenofovir gel microbicide trial.
    Mansoor LE; Abdool Karim Q; Yende-Zuma N; MacQueen KM; Baxter C; Madlala BT; Grobler A; Abdool Karim SS
    AIDS Behav; 2014 May; 18(5):811-9. PubMed ID: 24643315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Male circumcision at different ages in Rwanda: a cost-effectiveness study.
    Binagwaho A; Pegurri E; Muita J; Bertozzi S
    PLoS Med; 2010 Jan; 7(1):e1000211. PubMed ID: 20098721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial.
    Mansoor LE; Karim QA; Werner L; Madlala B; Ngcobo N; Cornman DH; Amico KR; Fisher J; Fisher WA; Macqueen KM; Karim SS
    AIDS Behav; 2014 May; 18(5):841-8. PubMed ID: 24633717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial.
    Sokal DC; Karim QA; Sibeko S; Yende-Zuma N; Mansoor LE; Baxter C; Grobler A; Frolich J; Kharsany AB; Miya N; Mlisana K; Maarshalk S; Karim SS
    Antivir Ther; 2013; 18(3):301-10. PubMed ID: 22914267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing adherence in the CAPRISA 004 tenofovir gel HIV prevention trial: results of a nested case-control study.
    MacQueen KM; Weaver MA; van Loggerenberg F; Succop S; Majola N; Taylor D; Karim QA; Karim SA
    AIDS Behav; 2014 May; 18(5):826-32. PubMed ID: 24647763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylactic treatment with a novel bioadhesive gel formulation containing aciclovir and tenofovir protects from HSV-2 infection.
    Shankar GN; Alt C
    J Antimicrob Chemother; 2014 Dec; 69(12):3282-93. PubMed ID: 25139839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.
    Kashuba AD; Gengiah TN; Werner L; Yang KH; White NR; Karim QA; Abdool Karim SS
    J Acquir Immune Defic Syndr; 2015 Jul; 69(3):264-9. PubMed ID: 26181703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
    Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM;
    Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaginal microbicides save money: a model of cost-effectiveness in South Africa and the USA.
    Verguet S; Walsh JA
    Sex Transm Infect; 2010 Jun; 86(3):212-6. PubMed ID: 20522634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.
    Schackman BR; Scott CA; Walensky RP; Losina E; Freedberg KA; Sax PE
    AIDS; 2008 Oct; 22(15):2025-33. PubMed ID: 18784465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of male circumcision for HIV prevention in a South African setting.
    Kahn JG; Marseille E; Auvert B
    PLoS Med; 2006 Dec; 3(12):e517. PubMed ID: 17194197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial.
    Mureithi MW; Poole D; Naranbhai V; Reddy S; Mkhwanazi NP; Sibeko S; Werner L; Abdool Karim Q; Abdool Karim S; Ndung'u T; Altfeld M;
    J Acquir Immune Defic Syndr; 2012 Jun; 60(2):124-7. PubMed ID: 22362152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis.
    Cremin I; Alsallaq R; Dybul M; Piot P; Garnett G; Hallett TB
    AIDS; 2013 Jan; 27(3):447-58. PubMed ID: 23296196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania.
    Gilson L; Mkanje R; Grosskurth H; Mosha F; Picard J; Gavyole A; Todd J; Mayaud P; Swai R; Fransen L; Mabey D; Mills A; Hayes R
    Lancet; 1997 Dec 20-27; 350(9094):1805-9. PubMed ID: 9428251
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring.
    Moss JA; Malone AM; Smith TJ; Kennedy S; Kopin E; Nguyen C; Gilman J; Butkyavichene I; Vincent KL; Motamedi M; Friend DR; Clark MR; Baum MM
    Antimicrob Agents Chemother; 2012 Feb; 56(2):875-82. PubMed ID: 22123689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-serodiscordant couples desiring a child: 'treatment as prevention,' preexposure prophylaxis, or medically assisted procreation?
    Mabileau G; Schwarzinger M; Flores J; Patrat C; Luton D; Epelboin S; Mandelbrot L; Matheron S; Yazdanpanah Y
    Am J Obstet Gynecol; 2015 Sep; 213(3):341.e1-12. PubMed ID: 25979615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of antiviral drug therapy to reduce mother-to-child HIV transmission in sub-Saharan Africa.
    Marseille E; Kahn JG; Saba J
    AIDS; 1998 May; 12(8):939-48. PubMed ID: 9631148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women in South Africa.
    Vickerman P; Devine A; Foss AM; Delany-Moretlwe S; Mayaud P; Meyer-Rath G
    Sex Transm Dis; 2011 May; 38(5):401-9. PubMed ID: 21317689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
    Brogan AJ; Talbird SE; Cohen C
    Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial.
    Wei X; Hunt G; Abdool Karim SS; Naranbhai V; Sibeko S; Abdool Karim Q; Li JF; Kashuba AD; Werner L; Passmore JA; Morris L; Heneine W; Johnson JA
    J Infect Dis; 2014 Jun; 209(12):1916-20. PubMed ID: 24436453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.